Education
About Us
Working with TipRanks
Follow Us
Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ:PHAT
Top Page
Phathom Pharmaceuticals
(NASDAQ:PHAT)
Select Model
Select Model
Rating:57Neutral
Price Target:
$14.00
▲(13.64% Upside)
Action:ReiteratedDate:01/09/26
The score is held back primarily by weak financial quality (large losses, cash burn, and negative equity) despite strong revenue growth and gross margins. Technicals and the latest earnings call are supportive due to clear momentum and sharply improved expense and cash usage trends, while valuation is constrained by negative earnings and the recent financing introduces dilution even as it improves liquidity.
Positive Factors
Revenue Growth & Gross Margins
Meaningful top-line scaling to $147M with ~87% gross margins signals attractive unit economics and successful commercialization of core products. Durable high gross margins mean incremental sales can flow to operating leverage, supporting a lasting path to profitability as fixed costs are managed.
Commercial Traction (Prescriptions)
Rapid prescription growth and a large installed base indicate sustained physician adoption and patient demand for VOQUEZNA. A durable prescription footprint supports recurring revenue, strengthens payer negotiation positions, and underpins multi-quarter commercialization momentum in GI therapeutics.
Low Financial Leverage
Very low reported debt reduces interest burden and refinancing exposure, preserving strategic optionality while the company scales. This durable low-leverage profile limits downside from rising rates and gives flexibility to prioritize commercialization and R&D investments over near-term debt service.
Negative Factors
Deep Negative Equity
A deeply negative equity position reflects cumulative losses that materially constrain balance sheet flexibility. This structural weakness limits the ability to access non-dilutive financing, restricts strategic alternatives, and raises vulnerability to setbacks that could force distress financing or heavy dilution.
Sustained Cash Burn / Weak Cash Generation
Persistent negative operating and free cash flow near $225M TTM shows the business continues to consume large amounts of cash despite expense reductions. This durable cash-burn profile necessitates external funding, limits reinvestment capacity, and delays the company's ability to self-fund growth or sustain operations without financing.
Reliance on Equity Financing / Dilution Risk
The recent ~$130M offering and automatic shelf filing indicate structural dependence on equity to fund operations and growth. Ongoing equity raises can dilute shareholders, signal limited internal cash sufficiency, and elevate funding risk until operating profitability and sustained positive cash flow are achieved.
Phathom Pharmaceuticals (PHAT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$909.00M
Dividend YieldN/A
Average Volume (3M)896.76K
Price to Earnings (P/E)―
Beta (1Y)2.23
Revenue Growth460.30%
EPS Growth33.03%
CountryUS
Employees427
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.29
Shares Outstanding78,294,780
10 Day Avg. Volume855,336
30 Day Avg. Volume896,761
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-2.02
Price to Sales (P/S)9.28
P/FCF Ratio-1.92
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue5.63
Enterprise Value/Gross Profit6.45
Enterprise Value/Ebitda-4.07
Forecast
1Y Price Target
$24.00Price Target Upside94.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.91
Revenue Forecast (FY)$314.17M
Phathom Pharmaceuticals Business Overview & Revenue Model
Company DescriptionPhathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
How the Company Makes MoneyPhathom Pharmaceuticals generates revenue primarily through the commercialization of its pharmaceutical products. The company's key revenue streams include sales from its marketed medications, which are aimed at treating gastrointestinal conditions. Additionally, Phathom may benefit from partnerships and collaborations with other pharmaceutical companies for co-development or licensing agreements, which can provide upfront payments, milestone payments, and royalties on sales. These collaborative efforts can enhance its financial stability and expand its market reach, contributing significantly to its overall earnings.
Phathom Pharmaceuticals Earnings Call Summary
Earnings Call Date:Feb 26, 2026
(Q4-2025)
| Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call conveyed meaningful operational and financial progress: very strong revenue growth (217% YoY), disciplined expense reductions, improved cash profile via a $130M equity raise and favorable term loan modifications, near-full sales force, and clear guidance to reach operating profitability in Q3 2026 and cash flow positivity in 2027. Key challenges cited include persistently high gross-to-net discounts (55%–59%), remaining absolute expense levels, seasonality and short-term prescription volatility, limited broad Medicare coverage, covenant timing considerations, and competitive risk. On balance, the positive execution items (revenue growth, cost control, capital structure improvements, and commercial traction) outweigh the challenges described.Q4-2025 Updates
Positive Updates
Strong Full-Year Revenue Growth
Full-year 2025 net revenues of $175.1 million, representing 217% year-over-year growth and delivering at the high end of the guided range.
Solid Q4 Performance and Quarterly Growth
Q4 2025 revenue of $57.6 million, in line with pre-release guidance and representing ~16% sequential quarterly growth.
Tight Expense Discipline and Reduced Cash Use
Q4 cash operating expenses (ex. stock-based comp.) of $50.3 million, better than the < $55M target and below prior preannounced ranges; company reduced quarterly cash operating expenses by nearly 50% over the last three quarters and reported Q4 net cash usage of ~$5 million (64% lower than Q3).
Improved Liquidity via Equity Raise
Completed an oversubscribed January equity offering that raised $130 million in gross proceeds, bringing pro forma cash to just north of $250 million at the start of the year.
Term Loan Modification Lowers Cost and Extends Maturity
Renegotiated term loan: remaining principal reduced to $175 million, interest rate lowered from 12% to 9.85% (≈215 bps reduction), maturity extended from Dec 2027 to Feb 2029; used ~ $56 million of cash to streamline the facility.
High Gross Margin and Stable Gross-Profit Profile
Reported gross margin of ~87% in Q4 and full year 2025; 2026 guidance expects ~80% gross margin (largely impacted by an accounting classification shift rather than underlying product economics).
Clear 2026 Operating Targets and Profitability Timeline
Issued 2026 guidance of $320M–$345M net revenue (includes a $17M–$20M reclassification), gross-to-net guidance of 55%–59%, cash operating expense guidance of $235M–$255M (midpoint ~14% decrease vs. 2025), and expectation to reach operating profitability (ex. stock-based comp.) beginning in Q3 2026 and cash flow positivity in 2027.
Commercial Traction and Sales Force Build
Over 1.1 million VOQUEZNA prescriptions filled to more than 230,000 patients through Feb 13; Q4 filled ~273,000 prescriptions with covered scripts (174k) up 21% quarter-over-quarter; sales organization nearly full strength with >285 of 300 positions filled (~95%).
Distribution and Access Enhancements
Expanded patient access channels: Blink network now handles >50% of prescriptions (36% are Blink-disbursed cash scripts) and launched a GoodRx cash-pay option in November to broaden affordability alternatives.
Negative Updates
High Gross-to-Net Discounts
Gross-to-net (rebate/discount) remains high: Q4 at the high end of a 55%–60% range and 2026 guidance of 55%–59%, materially reducing reported net revenue versus gross sales.
Ongoing Operating Losses (Improving but Present)
Although materially improved, the company still reported a loss from operations (excluding stock-based compensation) of approximately $320,000 in Q4; continuing high absolute cash operating expense ($284M for full-year 2025) remains a near-term profitability headwind despite reductions.
Seasonality and Near-Term Demand Volatility
Q1 is expected to be the weakest quarter due to typical seasonality; winter storms contributed to short-term softness and reporting lags, creating quarter-to-quarter volatility in prescription trends.
Medicare Coverage Limitations
No expectation of broad Medicare coverage changes; Medicare prescriptions may improve incrementally via appeals and selective Part D plan coverage, but broad systemic Medicare coverage is not anticipated in the near term.
Concentration vs. Large PPI Market Opportunity
Despite growth, VOQUEZNA penetration remains small relative to the PPI market (~1.1M VOQUEZNA scripts vs. ~110M PPI prescriptions/year), highlighting a long runway but current low market share and ongoing conversion effort needed.
Financial Covenant Timing and Cash Requirements
Revenue interest financing covenants will introduce a peak cash flow requirement of approximately $130 million between now and Sep 30, 2027 (company states current cash and forecasted operations will be sufficient, but the covenant timing represents a near-term obligation to monitor).
Data/Reporting Discrepancies
Management noted IQVIA prescription data appears to underreport versus internal metrics more than historically typical, introducing potential temporary visibility/analyst-modeling challenges until reconciled.
Competitive Risk Remains
Potential competitors (e.g., other P-CAB entrants such as tegoprazan) are progressing through development/approval paths; while management believes category expansion can be net positive, new entrants present competitive uncertainty for market dynamics.
Company Guidance
Phathom guided 2026 net revenue of $320–$345 million (including an accounting reclassification that shifts roughly $17–$20 million from gross‑to‑net to cost of goods sold), with gross‑to‑net expected at 55%–59% and gross margin of ~80%. They forecast cash operating expenses (ex‑stock‑based comp) of $235–$255 million (midpoint ≈14% below 2025 cash OpEx of ≈$284M), expect to reach operating profitability excluding stock‑based compensation by Q3 2026 and for full‑year 2026, and to achieve cash‑flow positivity in 2027; revenue cadence is expected to be ~40% H1 / ~60% H2 with Q1 the soft quarter. Management also noted post‑transaction cash on hand of ~ $190M (after a $130M gross equity raise and ≈$56M used to modify term debt), the highest covenant cash requirement of ≈$130M through 9/30/2027 under the revenue‑interest financing, and a modified term loan of $175M outstanding at 9.85% interest maturing February 2029.Phathom Pharmaceuticals Financial Statement Overview
Summary
Revenue growth and very strong gross margins show solid commercialization progress, and reported debt is low. However, large operating/net losses, substantial negative free cash flow, and deeply negative equity keep financial risk elevated and limit flexibility.Income Statement
TTM (Trailing-Twelve-Months) revenue scaled meaningfully to $147.2M and grew 29.1%, following a sharp step-up in 2024 ($55.3M, up 80.0% year over year), showing strong commercialization momentum. Gross profit is also robust in TTM with an ~87% gross margin, indicating attractive unit economics. However, profitability remains the key drag: TTM operating and net losses are large (net margin roughly -187%), reflecting a cost structure that is still far ahead of the current revenue base. Overall, the top-line trajectory is encouraging, but the income statement is still dominated by heavy losses.32
Negative
Balance Sheet
The balance sheet is pressured by sustained losses that have pushed stockholders’ equity deeply negative (TTM about -$422.5M, versus -$253.6M in 2024), which materially reduces financial flexibility and increases refinancing/dilution risk over time. A positive is that reported total debt is very low in TTM (~$2.7M), a sharp improvement versus 2024 (~$554.9M), suggesting the company is not currently burdened by balance-sheet leverage. Even so, negative equity remains the central weakness and signals a fragile capital position despite the lighter debt load.24
Negative
Cash Flow
Cash generation remains weak: TTM operating cash flow and free cash flow are both around -$225M, and free cash flow declined further versus the prior period (TTM free cash flow growth about -18%). While cash burn improved from 2024 (operating cash flow about -$266.8M), the business is still consuming substantial cash and free cash flow remains firmly negative. This keeps funding needs elevated and leaves the company dependent on external capital until losses and burn compress materially.20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 147.19M | 55.25M | 682.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 128.42M | 47.28M | 515.00K | -620.00K | -521.00K | -300.00K |
| EBITDA | -203.56M | -261.52M | -159.05M | -169.80M | -136.57M | -124.19M |
| Net Income | -274.55M | -334.33M | -201.59M | -197.72M | -143.88M | -129.07M |
Balance Sheet | ||||||
| Total Assets | 240.29M | 378.32M | 413.84M | 164.81M | 189.43M | 295.11M |
| Cash, Cash Equivalents and Short-Term Investments | 135.16M | 297.26M | 381.39M | 155.38M | 183.26M | 287.50M |
| Total Debt | 2.71M | 554.95M | 139.03M | 97.07M | 91.34M | 49.02M |
| Total Liabilities | 662.82M | 631.90M | 486.60M | 239.62M | 117.28M | 100.84M |
| Stockholders Equity | -422.53M | -253.58M | -72.76M | -74.81M | 72.16M | 194.27M |
Cash Flow | ||||||
| Free Cash Flow | -225.25M | -266.90M | -139.21M | -147.57M | -148.78M | -70.73M |
| Operating Cash Flow | -225.23M | -266.77M | -137.58M | -146.53M | -148.46M | -69.69M |
| Investing Cash Flow | -147.00K | -135.00K | -1.63M | -1.04M | -328.00K | -1.04M |
| Financing Cash Flow | 25.86M | 182.77M | 367.58M | 120.04M | 44.71M | 114.46M |
Phathom Pharmaceuticals Technical Analysis
Neutral
12.32
Price Trends
14.43
Negative
14.08
Negative
11.57
Positive
Market Momentum
-0.72
Negative
44.25
Neutral
36.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHAT, the sentiment is Neutral. The current price of 12.32 is below the 20-day moving average (MA) of 12.60, below the 50-day MA of 14.43, and above the 200-day MA of 11.57, indicating a neutral trend. The MACD of -0.72 indicates Negative momentum. The RSI at 44.25 is Neutral, neither overbought nor oversold. The STOCH value of 36.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PHAT.
Phathom Pharmaceuticals Risk Analysis
Phathom Pharmaceuticals disclosed 84 risk factors in its most recent earnings report. Phathom Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Phathom Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | $909.00M | ― | ― | ― | 460.30% | 33.03% | |
54 Neutral | $1.24B | -13.36 | -34.05% | ― | 522.13% | 62.68% | |
53 Neutral | $1.34B | -13.17 | -64.93% | ― | -36.36% | -945.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.40B | -5.75 | -68.33% | ― | ― | -38.04% | |
50 Neutral | $971.28M | -5.97 | ― | ― | 8.00% | -10.15% | |
41 Neutral | $857.77M | -20.74 | -45.88% | ― | 116.64% | 47.93% |
* Healthcare Sector Average
PHAT
Phathom Pharmaceuticals
12.32
6.56
113.89%
GERN
Geron
1.72
-0.02
-1.15%
ABUS
Arbutus Biopharma
4.60
1.23
36.50%
URGN
Urogen Pharma
20.67
11.38
122.50%
TSHA
Taysha Gene Therapies
4.67
3.08
193.71%
ZBIO
Zenas BioPharma, Inc.
26.03
19.42
293.80%
Phathom Pharmaceuticals Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Phathom Pharmaceuticals Announces $130 Million Public Offering
Positive
Jan 8, 2026
On January 7, 2026, Phathom Pharmaceuticals entered into an underwriting agreement with Guggenheim Securities and Cantor Fitzgerald for an underwritten public offering comprising 6,875,000 shares of common stock at $16.00 per share and 1,250,078 pre-funded warrants at $15.999 each, with a 30-day option for underwriters to purchase up to 1,218,761 additional shares. The underwriters agreed to purchase the securities at a discount, and Phathom expects to raise net proceeds of about $130 million, or approximately $150 million if the option is fully exercised, with the offering anticipated to close on January 9, 2026 subject to customary conditions; the company has said it plans to use the capital for general corporate purposes, including working capital and commercialization and R&D expenses, which would bolster its funding base for ongoing product rollouts and pipeline development in gastrointestinal therapeutics.
The most recent analyst rating on (PHAT) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on Phathom Pharmaceuticals stock, see the PHAT Stock Forecast page.
Business Operations and StrategyProduct-Related Announcements
Phathom Pharmaceuticals Begins Phase 2 EoE Trial
Neutral
Nov 4, 2025
On November 4, 2025, Phathom Pharmaceuticals announced the commencement of its Phase 2 pHalcon EoE-201 clinical trial, marking the first dosing of a patient with VOQUEZNA® (vonoprazan) tablets for eosinophilic esophagitis in adults. This two-part, randomized, double-blind, placebo-controlled study aims to enroll 80 adults with EoE and dysphagia, with results expected in 2027, potentially impacting Phathom’s market position in gastrointestinal treatments.
The most recent analyst rating on (PHAT) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Phathom Pharmaceuticals stock, see the PHAT Stock Forecast page.
Business Operations and StrategyProduct-Related Announcements
Phathom Pharmaceuticals Publishes Phase 3 Trial Results
Positive
Oct 27, 2025
On October 25, 2025, Phathom Pharmaceuticals announced the publication of additional analyses from its Phase 3 pHalcon-NERD-301 trial in the American Journal of Gastroenterology, highlighting the effectiveness of VOQUEZNA® (vonoprazan) tablets in treating nighttime symptoms of Non-Erosive Reflux Disease (NERD). The trial demonstrated that VOQUEZNA significantly improved the percentage of heartburn-free nights and was generally well tolerated, offering a promising alternative for patients who experience inadequate relief from existing treatments. This development could enhance Phathom’s positioning in the gastrointestinal treatment market by addressing a significant gap in current GERD therapies.
The most recent analyst rating on (PHAT) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Phathom Pharmaceuticals stock, see the PHAT Stock Forecast page.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.